Premium
Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative
Author(s) -
Wooten Robert S.,
Smith Kevin C.,
Ahlquist David A.,
Muller Sigfrid A.,
Balm Rita K.
Publication year - 1988
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/lsm.1900080312
Subject(s) - hematoporphyrin , phototoxicity , medicine , dermatology , photosensitivity , hyperpigmentation , prospective cohort study , photodermatosis , incidence (geometry) , surgery , anesthesia , photodynamic therapy , biology , optics , in vitro , dna damage , dna , biochemistry , chemistry , physics , genetics , organic chemistry , xeroderma pigmentosum , quantum mechanics
Hematoporphyrin derivative (HpD) is a photoactive, oncophilic substance that produces cutaneous photosensitivity as its only significant side effect. Twenty‐three patients who received systemic HpD and the usual light‐avoidance precautions were studied prospectively to determine the incidence and severity of cutaneous phototoxicity (CP). Seventeen of the 23 patients (74%) reported CP, including three patients (18%) who experienced blister formation. Symptoms of CP occurred for a mean duration of 6 weeks (range 5–23 weeks). Lack of compliance with restrictive photoprotective measures was felt to be a major contributing factor. Other HpD‐related complications included skin hyperpigmentation, ocular discomfort, pruritus, pain at injection site, and urticaria. CP and the restrictive measures to avoid it represent major disadvantages of the clinical use of HpD.